Systemic Lupus Erythematosus clinical trials

Explore recruiting systemic lupus erythematosus clinical trials.

Recruiting systemic lupus erythematosus studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Systemic Lupus Erythematosus trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obinutuzumab in Patients with Systemic Lupus Erythematosus

France, Poland, Italy, Czechia, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Randomised, placebo-controlled, double-blind, parallel-group Phase II study to evaluate the efficacy and safety of oral BI 3000202 in patients with moderate to severe systemic lupus erythematosus (SLE)

Bulgaria, Romania, Germany, Spain, Hungary, Poland +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Double-blind, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)

Germany, Romania, France, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

OPUS-2 - Oral S1P1 Receptor ModUlation in SLE: A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy

Spain, Germany, Portugal, Poland, Czechia

Therapeutic confirmatory (Phase III) EU CTIS Study details

Efficacy and safety of SAR441344 in the treatment of Systemic Lupus Erythematosus: A randomized, double blind, placebo-controlled, Phase 2, proof of concept study.

Spain, Greece, Italy, Hungary

Therapeutic exploratory (Phase II) EU CTIS Study details

An open-label, multi-center, phase 1/2 study to assess safety, efficacy and cellular kinetics of YTB323 in participants with severe, refractory systemic lupus erythematosus (srSLE).

Spain, France, Germany

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Systemic Lupus Erythematosus trials by city

Systemic Lupus Erythematosus in Toronto Systemic Lupus Erythematosus in Vancouver Systemic Lupus Erythematosus in Montreal Systemic Lupus Erythematosus in Calgary Systemic Lupus Erythematosus in Edmonton Systemic Lupus Erythematosus in Ottawa Systemic Lupus Erythematosus in Winnipeg Systemic Lupus Erythematosus in Quebec City Systemic Lupus Erythematosus in Hamilton Systemic Lupus Erythematosus in Kitchener Systemic Lupus Erythematosus in London Systemic Lupus Erythematosus in Halifax Systemic Lupus Erythematosus in New York Systemic Lupus Erythematosus in Los Angeles Systemic Lupus Erythematosus in Chicago Systemic Lupus Erythematosus in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease